中国药房2023，Vol.34Issue(24)：3068-3072,5.DOI:10.6039/j.issn.1001-0408.2023.24.21
英夫利西单抗用于克罗恩病患者的治疗药物监测研究进展
Advances in therapeutic drug monitoring of infliximab in patients with Crohn disease
摘要
Abstract
Infliximab(IFX),tumor necrosis factor-α inhibitor,is widely used in clinical practice for treating Crohn disease(CD),but it is difficult to obtain the optimal therapeutic effect according to the conventional dose.It is recommended to perform therapeutic drug monitoring(TDM)for patients with poor therapeutic efficacy to guide clinical decisions.This paper reviews the pharmacokinetic characteristics of IFX,exposure-response relationship,the influencing factors of pharmacokinetic differences,and analytical methods in TDM.It is found that IFX doesn't undergo liver or kidney metabolism,exhibits obvious exposure-response relationships in both the induction and maintenance phases of CD treatment;disease activity,albumin,antibodies to IFX(ATI)and other factors influence IFX's exposure.It is recommended that trough concentration of IFX in the maintenance period should be kept above 3 μg/mL;the dose of IFX should be increased or medication interval should be shortened for patients with severe disease,low albumin levels and ATI formation,to promote therapeutic efficacy of IFX.It is suggested to use the same detection method for TDM of IFX in the same patient.关键词
英夫利西单抗/克罗恩病/治疗药物监测/暴露-效应关系/药动学差异Key words
infliximab/Crohn disease/therapeutic drug monitoring/exposure-response relationship/pharmacokinetic variation分类
医药卫生引用本文复制引用
朱扣柱,王燕,缪丽燕..英夫利西单抗用于克罗恩病患者的治疗药物监测研究进展[J].中国药房,2023,34(24):3068-3072,5.基金项目
苏州市姑苏卫生人才培养项目(No.GSWS2019001) （No.GSWS2019001）
